Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Machine Learning Model Uses Blood Tests to Predict Survival of Critically Ill COVID-19 Patients

By HospiMedica International staff writers
Posted on 20 Jan 2022

A single blood sample from a critically ill COVID-19 patient can be analyzed by a machine learning model which uses blood plasma proteins to predict survival, weeks before the outcome, according to a new study. More...

Scientists at the Charité-Universitätsmedizin Berlin (Berlin, Germany) have found that the levels of 14 proteins in the blood of critically ill COVID-19 patients are associated with survival. Healthcare systems around the world are struggling to accommodate high numbers of severely ill COVID-19 patients who need special medical attention, especially if they are identified as being at high risk. Clinically established risk assessments in intensive care medicine, such as the SOFA or APACHE II, show only limited reliability in predicting future disease outcomes for COVID-19.

In the new study, researchers studied the levels of 321 proteins in blood samples taken at 349 timepoints from 50 critically ill COVID-19 patients being treated in two independent health care centers in Germany and Austria. A machine learning approach was used to find associations between the measured proteins and patient survival. 15 of the patients in the cohort died; the average time from admission to death was 28 days. For patients who survived, the median time of hospitalization was 63 days.

The researchers pinpointed 14 proteins which, over time, changed in opposite directions for patients who survive compared to patients who do not survive on intensive care. The team then developed a machine learning model to predict survival based on a single time-point measurement of relevant proteins and tested the model on an independent validation cohort of 24 critically ill COVID-10 patients. The model demonstrated high predictive power on this cohort, correctly predicting the outcome for 18 of 19 patients who survived and five out of five patients who died.

The researchers concluded that blood protein tests, if validated in larger cohorts, may be useful in both identifying patients with the highest mortality risk, as well as for testing whether a given treatment changes the projected trajectory of an individual patient.

Related Links:
Charité-Universitätsmedizin Berlin 


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.